Owing to the potential danger of spreading COVID – 19 and as directed by AMFI, to ensure safety of our investors, partners and employees, all our AMC branches are temporarily closed until further notice. However, we will be working from home and will be at your service. We urge our investors and partners to make use of various other digital modes available for making transactions. For any queries, please write to us at crmf@canararobeco.com. You may also call us at 1800-209-2726 during working hours.
We will be continuously monitoring the situation and shall update the status once the normal operations are resumed. We would like to reiterate that serving you well is our top priority and shall attempt to make your investment journey a memorable one with Canara Robeco.
With effect from December 9, 2013, U.S. Persons and Residents of Canada are not permitted to invest in any of the Schemes of Canara Robeco Mutual Fund. Read the issuednotice cum addendum in this reference.
This product is suitable for investors who are seeking *
Income / capital appreciation over short term
Investment in debt & money market instruments such that the Macaulay duration of the portfolio is between 1 year and 3 years
* Investors should consult their financial advisers if in doubt above whether the product is suitable for them.
* Investors should consult their financial advisers if in doubt above whether the product is suitable for them.
Comparative performance of Canara Robeco Short Duration Fund - Growth
| Canara Robeco Short Duration Fund - Growth | Scheme Benchmark (CRISIL Short Duration Debt A-II Index) | Additional Benchmark (CRISIL 10 Yr Gilt Index) | |
|---|---|---|---|
| CAGR since Inception | 6.73 % | NA | 6.68 % |
| 1 Year | 7.40 % | NA | 10.39 % |
| 3 Year | 5.29 % | NA | 5.56 % |
| 5 Year | 5.51 % | NA | 5.48 % |
| Current Value of 10,000 invested at inception | ` 24257.00 | NA | ` 24098.00 |
Debt and Money Market instruments- 0% to 100% (Risk- Low to Medium)
Reits / Invits- 0% to 10% (Risk- Medium to High)
Equities0.00%
Debt Instruments58.03%
Government Bonds26.48%
Money Market0.71%
Others7.60%
Asset Allocation as on
Modified duration (in Years)2.35
Average maturity (in Years)2.94
Yield to maturity7.58 %
Macaulay Duration2.47
Regular Plan1.02 %
Direct Plan0.43 %
Note – Scheme may or may not have any future position in the above Sectors(s) / Stock(s) / Issuer(s)
NAV As on 20-Dec-2024
11.5770.00 (-0.03%)CAGRSince Inception
6.48%Moderate Risk
This product is suitable for investors who are seeking *
Income/ Capital appreciation over short to medium term
Investments in debt and money market instruments issued by Banks, Public Sector Undertakings (PSUs), Public Financial Institutions (PFIs) and Municipal Bonds
* Investors should consult their financial advisers if in doubt above whether the product is suitable for them.
NAV As on 20-Dec-2024
20.8761-0.01 (-0.05%)CAGRSince Inception
7.00%Moderate Risk
This product is suitable for investors who are seeking *
Income / capital appreciation through a low credit risk strategy
Investment in a portfolio constituted predominantly of AA+ and above rated corporate bonds
* Investors should consult their financial advisers if in doubt above whether the product is suitable for them.
NAV As on 20-Dec-2024
28.2914-0.02 (-0.08%)CAGRSince Inception
6.91%Moderate Risk
This product is suitable for investors who are seeking *
Income/ Capital appreciation by dynamically managing duration
Investment in Debt and Money Market securities across duration
* Investors should consult their financial advisers if in doubt above whether the product is suitable for them.
NAV As on 20-Dec-2024
72.6177-0.06 (-0.08%)CAGRSince Inception
8.26%Moderate Risk
This product is suitable for investors who are seeking *
Risk free return (except interest rate risk) and long term capital appreciation
Investment in government securities across maturity
* Investors should consult their financial advisers if in doubt above whether the product is suitable for them.
NAV As on 20-Dec-2024
53.3761-0.02 (-0.04%)CAGRSince Inception
7.81%Moderate Risk
This product is suitable for investors who are seeking *
Income / Capital appreciation over Medium to Long term
Investment in debt & money market instruments such that the Macaulay duration of the portfolio is between 4 years and 7 years (Portfolio Macaulay duration under anticipated adverse situation is 1 year to 7 years)
* Investors should consult their financial advisers if in doubt above whether the product is suitable for them.
NAV As on 22-Dec-2024
3030.608640.58 (0.02%)CAGRSince Inception
6.94%Low to Moderate Risk
This product is suitable for investors who are seeking *
Income/ Capital appreciation while maintaining a level of high liquidity
Investment in a mix of Debt and Money Market instruments with maturity of upto 91 days only
* Investors should consult their financial advisers if in doubt above whether the product is suitable for them.
NAV As on 22-Dec-2024
1295.522710.23 (0.02%)CAGRSince Inception
4.89%Low Risk
This product is suitable for investors who are seeking *
Regular income over short term that may be in line with the overnight call rates.
Investment in overnight securities.
* Investors should consult their financial advisers if in doubt above whether the product is suitable for them.
NAV As on 20-Dec-2024
40.4430.00 (0.01%)CAGRSince Inception
7.31%Low to Moderate Risk
This product is suitable for investors who are seeking *
Income / Capital appreciation through a low duration strategy
Investment in debt & money market instruments such that the Macaulay duration of the portfolio is between 6 months and 12 months
* Investors should consult their financial advisers if in doubt above whether the product is suitable for them.
NAV As on 20-Dec-2024
3660.0130.47 (0.01%)CAGRSince Inception
6.80%Low to Moderate Risk
This product is suitable for investors who are seeking *
Income/ Capital appreciation over ultra-short term through a low risk strategy
Investment in a mix of Debt and Money Market instruments such that the Macaulay duration of the portfolio is between 3 months and 6 months
* Investors should consult their financial advisers if in doubt above whether the product is suitable for them.
